Pain was almost ubiquitous among patients with multiple subtypes of multiple sclerosis, finds a study. Pain was almost omnipresent in measured subtypes of multiple sclerosis (MS), where over one-third ...
Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both ...
A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS). Having a university education was ...
East Hanover, NJ. October 4, 2022. John DeLuca, PhD, and Brian M. Sandroff, PhD, of Kessler Foundation provided expert commentary on a current controversy in the management of persons with multiple ...
Multiple Sclerosis (MS) is almost always accompanied by fatigue, a massive tiredness that is described by the vast majority of patients as the most distressing symptom. In a recent scientific study, a ...
Multiple Sclerosis (MS) is almost always accompanied by fatigue, a massive tiredness that is described by the vast majority of patients as the most distressing symptom. In a recent scientific study, a ...
Machine learning can help predict whether people newly diagnosed with MS will experience disability worsening that occurs ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
About 100,000 of the estimated million people in the United States with multiple sclerosis (MS) have a progressive form of the disease, with symptoms that worsen continuously or after periods of ...
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results